![]() | Review waiting, please be patient.
This may take 3 months or more, since drafts are reviewed in no specific order. There are 1,957 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 10 August 2024 by CFA (talk). This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. | ![]() |
Submission declined on 23 July 2024 by SafariScribe (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by SafariScribe 40 days ago. | ![]() |
Comment: See Wikipedia:Articles for deletion/Anand Reddi (2nd nomination). C F A 💬 17:47, 10 August 2024 (UTC)
Comment: Thank you @SafariScribe and @CFA for the excellent feedback and very thoughtful responses to improve the article. 1. The references have been improved including notable 3rd party new sources since the initial submission per @SafariScribe. 2. The draft has been significantly re-written to reflect the editorial comments from @CFA on encyclopedic quality as well as past comments on the deletion comments posted by CFA that existed on the Wikipedia page that was live from 2012-2024. The provision of antiretroviral therapy in the resource limited settings of Africa is extremly important topic as the donor community recommits funding for HIV scale-up in Africa as well as pandemic preparedness. The work of this subject matter expert is important to profile given the current debates. 💬 17:47, 16 August 2024 (UTC)
Anand Reddi | |
---|---|
Born | Maryland, USA |
Nationality | American |
Education | University of Michigan, Ann Arbor, University of Colorado School of Medicine |
Occupation(s) | Global Health Policy Advocate, Public Health Specialist, Biotech Executive |
Known for | Advocacy in global HIV/AIDS treatment and health systems strengthening |
Awards | Fulbright Scholar, American Medical Association Foundation Leadership Award |
Anand Reddi is a health system strengthening expert, global health specialist and public health advocate. His early work focused on global HIV scale-up including the President's Emergency Plan for AIDS Relief (PEPFAR).[1][2][3][4][5][6][7] Since 2015, Reddi works in the biotech industry advancing access to essential medicines and building global public-private health partnerships.[8][9][10][11] He served on several global health not-for-profit board of directors including the AIDS Healthcare Foundation and the Bay Area Global Health Alliance.[12]
Early Life and Education
editReddi pursued his undergraduate studies in history and biology at the University of Michigan, Ann Arbor and a medical degree at the University of Colorado School of Medicine.[13][14] He was a Fulbright Scholar to KwaZulu-Natal, South Africa, focusing on pediatric antiretroviral scale-up under the research mentorship of Hoosen Coovadia and Quarraisha Abdool Karim at the PEPFAR funded Sinikithemba HIV/AIDS clinic at McCord Zulu Hospital.[15][16]
Global Health Research
editIn the early 2000s it was uncertain if the provision of antiretroviral therapy in resource limited settings such as Southern Africa was feasible.[17] Reddi's research demonstrated that antiretroviral therapy is effective despite the challenges of a resource limited setting.[18] The nexus of syndemics that co-localize with HIV suggested how interconnected health issues, such as food insecurity and economic privation, interact and exacerbate each other alongside an infectious disease.[19] This work lead to the conceptual advance that integrated healthcare approaches including family centered care models can improve antiretroviral treatment outcomes.[20] These data were important in providing implementation experience for HIV scale-up initiatives advanced by PEPFAR and The Global Fund.[21] The implementation science work appeared in AIDS, Journal of Acquired Immune Deficiency Syndromes and Science. Opinion pieces in The Huffington Post, The New York Times and The Washington Post were also published to translate academic findings into public health policy in a field called "translational advocacy."[22][23][24][25][26]
Reddi's advocacy brought attention to the flatlining of global AIDS funding by U.S. President Barack Obama's administration.[27][28][29][30] Within six hours, Ezekiel Emanuel, President Obama's senior adviser for Health Policy, responded directly to Reddi by writing in The Huffington Post: "Contrary to what Dr. Reddi argues, neither I nor the Obama Administration sees an "either-or" trade-off between PEPFAR and other global health priorities such as improving maternal-child health".[31] Reddi and Archbishop Desmond Tutu alongside other HIV advocates rebutted Emanuel's arguments that resulted in the restoration of $366 million for antiretroviral scale-up in Uganda in 2010.[32][33]
In 2011, the AIDS Healthcare Foundation (AHF) launched a campaign against the Food and Drug Administration review of Truvada for use as a HIV Pre-exposure Prophylaxis (PrEP) drug.[34] Reddi resigned from the Board of Directors of AHF over their opposition to HIV PrEP writing: "AHF’s media campaign against FDA review of PrEP is myopic, blinded by its determination to derail a promising new medication."[35] In 2015, the World Health Organization recommended that people at substantial risk of HIV infection should be offered tenofovir disoproxil fumarate (TDF)-based oral PrEP as an additional HIV prevention option.[36]
To address the shortage of healthcare workers in resource limited settings such as Southern Africa, Reddi proposed the utilization of human capital contracts for global health building on the work of the Noble Prize in Economic Sciences winner Milton Friedman.[37][38][39][40] The idea proposed is that an investor, such as a donor nation, charitable foundation like the Gates Foundation, or global health initiative, will cover the entire cost of a student's medical training. In exchange, the student will work for the first 10 years of their medical career in a government or NGO sponsored health clinic in their respective country of medical education. Their medical license will be contingent on this obligatory national service. Additionally, a multilateral “binding” agreement between the African country and destination countries (such as Australia, Canada, New Zealand, United Kingdom, and the United States)-brokered by the investor- could prevent migration during the term period to mitigate the potential for "brain-drain".[41]
At Gilead Sciences, Reddi spearheaded one of the largest HIV Test & Treat projects in collaboration with The Vatican in Shinyanga, Tanzania.[42][2] The public private partnership between the biotech industry, the Vatican, Tanzanian government and HIV/AIDS NGOs such as Doctors with Africa CUAMM and Joep Lange's Amsterdam Institute of Global Health and Development pioneered a decentralized HIV test & treat outreach campaign to find at-risk populations, ultimately testing over 300,000 people and linking those HIV-positive to treatment.[1] Outcomes from the Tanzania Test & Treat project between May 2017 and June 2019 were 255,329 HIV tests performed and the overall HIV positivity rate was 1.2%.[43]
Awards
editReddi received the Atlantic Dialogues Emerging Leader Award, the American Medical Association Foundation Leadership Award and the Fulbright Scholarship to South Africa for his contributions in global health policy and HIV/AIDS treatment and advocacy.[44][14][16]
References
edit- ^ a b Nuki, Paul; Townsley, Simon (18 July 2018). "HIV and Aids in Africa has a new adversary – God and big pharma". The Telegraph.
- ^ a b Ratcliffe, Rebecca (22 July 2018). "Biker nun on a mission to free Tanzania from grip of HIV". The Guardian.
- ^ Liu, Richard (19 November 2020). "Atlantic Dialogues Talks 2020: Health Capacities as a New Power Instrument". The Atlantic Dialogues: Policy Center for the New South.
- ^ Purvis, Katherine. "How do we increase the HIV response with limited funds?". The Guardian. Retrieved 6 July 2024.
- ^ Banning-Lover, Rachel. "What is the best model to bring healthcare to all?". The Guardian. Retrieved 19 June 2024.
- ^ Mungcal, Ivy (18 October 2011). "Anand Reddi: PEPFAR at Risk Should Mitt Romney Become US President". Devex.
- ^ Judem, Emily. "An invisible issue: The presidential campaign and HIV/AIDS". The World Radio Program.
- ^ "Pharma companies are capitalizing on Covid-19 restrictions to promote unbranded campaigns". Pharmaceutical Technology Review. Retrieved 23 July 2024.
- ^ Bulik, Beth Snyder (28 Oct 2020). "BI, Gilead execs highlight value of disease awareness campaigns—particularly during the pandemic". Fierce Pharma.
- ^ "Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials". The Globe and Mail. 30 March 2021.
- ^ "Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati". NASDAQ. 28 June 2022.
- ^ "Speaking out on Social/Political issues: CHRO's role in working with CEO". HR Strategy Forum. Retrieved 8 July 2024.
- ^ "Anand Reddi, Director of Hepion Pharmaceuticals Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934". UNITED STATES SECURITIES AND EXCHANGE COMMISSION.
- ^ a b "Achievements in academics, service recognized with CU's 2013 Jefferson Award". University of Colorado. Retrieved 7 July 2024.
- ^ "Michigan News". Michigan Today.
- ^ a b "Grantee Directory". us.fulbrightonline.org. Retrieved 2024-07-24.
- ^ Herbert, Bob (11 June 2001). "In America; Refusing To Save Africans". The New York Times.
- ^ Reddi, Anand; Leeper, Sarah C.; Grobler, Anneke C.; Geddes, Rosemary; France, K Holly; Dorse, Gillian L.; Vlok, Willem J.; Mntambo, Mbali; Thomas, Monty; Nixon, Kristy; Holst, Helga L.; Karim, Quarraisha Abdool; Rollins, Nigel C.; Coovadia, Hoosen M.; Giddy, Janet (17 March 2017). "Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa". BMC Pediatrics. 7 (12): 13. doi:10.1186/1471-2431-7-13. PMC 1847430. PMID 17367540.
- ^ Reddi, Anand; Powers, Matthew A.; Thyssen, Andreas (2012-01-02). "HIV/AIDS and food insecurity: deadly syndemic or an opportunity for healthcare synergism in resource-limited settings of sub-Saharan Africa?". AIDS. 26 (1): 115–117. doi:10.1097/QAD.0b013e32834e14ac. ISSN 0269-9370. PMID 22126815.
- ^ Reddi, Anand; Leeper, Sarah; Sunpath, Henry (2008). "Pediatric highly active antiretroviral therapy in Africa: potential benefits of a family-centered model". Journal of Infectious Diseases. 198 (6): 938–939. doi:10.1086/591137. PMID 18721063.
- ^ Leeper, Sarah C; Reddi, Anand (2010-09-10). "United States global health policy: HIV/AIDS, maternal and child health, and The President's Emergency Plan for AIDS Relief (PEPFAR)". AIDS. 24 (14): 2145–2149. doi:10.1097/QAD.0b013e32833cbb41. ISSN 0269-9370. PMID 20606571.
- ^ "U.S. Global Health Policy: HIV/AIDS at a Crossroads Initial Accomplishments Threatened by Policy Changes". University of Colorado School of Medicine. CU Medicine Today. Retrieved 6 July 2024.
- ^ "Contributor:Anand Reddi". The Huffington Post. Retrieved 19 June 2024.
- ^ "Aids: Time to Refocus (2 Letters)". The New York Times. 1 Nov 2010.
- ^ "AIDS funds could be gained in a tax on currency speculation". The Washington Post. 19 Jan 2011. Retrieved 13 July 2024.
- ^ "AIDS/HIV funding must be a priority for the U.S." The Washington Post. 3 August 2010.
- ^ D'Almeida, Kanya. "Obama AIDS Plan Stumbles over Funding". Global Issues. Inter Press Service. Retrieved 19 June 2024.
- ^ Reddi, Anand (21 June 2010). "United States Global Health Policy: HIV/AIDS Treatment Funding At Risk Under President Obama". The Huffington Post.
- ^ Khan, Azmat (19 July 2012). "What Is President Obama's Track Record on HIV/AIDS?". Frontline (PBS).
- ^ Mungcal, Ivy (22 July 2010). "Eric Goosby, Bill Clinton Defend Obama's AIDS Funding Decisions". Devex.
- ^ Emanuel, Ezekiel J (21 July 2010). "The HIV/AIDS Fight Needs Cooperation, Not Division". The Huffington Post.
- ^ Tutu, Desmond (2010-07-21). "Opinion | Obama's Overdue AIDS Bill". The New York Times. ISSN 0362-4331. Retrieved 2024-08-12.
- ^ Mungcal, Ivy (23 July 2010). "Obama Promises to Step Up AIDS Fight". Devex.
- ^ "AHF to Gilead: "No Magic Pill" Ads Warn against AIDS Drug as HIV Prevention". AIDS Healthcare Foundation. 9 March 2011.
- ^ "Moving Forward on FDA Review of HIV Prevention Drugs". The Huffington Post. 2 Nov 2011.
- ^ World Health Organization. "Pre-exposure prophylaxis (PrEP)". Global HIV Program: PrEP. Retrieved 12 June 2024.
- ^ Grosshoff, David; Nguyen, Alex; Urien, Curtis. CROWDFUNDING 6.0: DOES THE SEC's FINTECH LAW FAILURE REVEAL THE AGENCY'S TRUE MISSION TO PROTECT-SOLELY ACCREDITED- INVESTORS? (PDF). THE OHIO STATE ENTREPRENEURIAL BUSINESS LAW JOURNAL. Retrieved 22 July 2024.
- ^ "Global Health Service Corps Essential To Improve African Health Systems, Achieve 'AIDS-Free Generation'". Kaiser Family Foundation.
- ^ Reddi, Anand; Thyssen, Andreas. "Healthcare Reform: Solving the Medical Student Debt Crisis Through Human Capital Contracts". The Huffington Post.
- ^ Weinstein, Louis; Wolfe, Honor (1 July 2010). "A unique solution to solve the pending medical school tuition crisis". American Journal of Obstetrics and Gynecology. 203 (1): 19.e1–19.e3. doi:10.1016/j.ajog.2009.11.019. PMID 20035918.
- ^ Reddi, A.; Thyssen, A.; Smith, D.; Lange, J. H.; Akileswaran, C. (2012). "Human capital contracts for global health: a plan to increase the number of physicians in resource limited settings". AIDS. 26 (15): 1979–1980. doi:10.1097/QAD.0b013e32835857d4. PMID 22992581.
- ^ Tanzania, World Health Organization. "The Tanzania Catholic Church launches the Test and Treat Project". WHO Tanzania. Retrieved 12 June 2024.
- ^ Martelli, Giulia; Van Duffel, Lukas; Kwezi, Edith Cosmas; Cavallin, Francesco; Salehe, Idd Amiri; Torelli, Giovanni F.; Putoto, Giovanni; Hermans, Sabine; Rinke De Wit, Tobias F.; Pozniak, Anton (2022). "Community- and facility-based HIV testing interventions in northern Tanzania: Midterm results of Test & Treat Project". PLOS ONE. 17 (4): e0266870. Bibcode:2022PLoSO..1766870M. doi:10.1371/journal.pone.0266870. PMC 9004748. PMID 35413074.
- ^ "Anand Reddi | Policy Center". www.policycenter.ma. Retrieved 2024-07-24.
Category:HIV/AIDS researchers
Category:University of Michigan alumni
Category:University of Colorado School of Medicine alumni
Category:American scientists
Category:Scientists from Maryland
Category:21st-century scientists
Category:Living people
Category:Year of birth missing (living people)
Category:American HIV/AIDS activists
Category:American health activists